drugset / Trial / NCT00057954
Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma
Phase 2
Terminated
6 enrolled
Eastern Cooperative Oncology Group
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Photopheresis allows patient white blood cells to be treated with ultraviolet (UV) light and drugs outside the body to inactivate T cells. Pentostatin may suppress the immune system and reduce the chance of developing graft-versus-host disease (GVHD) following bone marrow transplantation. Combining photopheresis with pentostatin and total-body irradiation may be effective in killing cancer cells before bone marrow transplantation. PURPOSE: This phase II trial is studying how well giving photophoresis together with pentostatin and total-body irradiation as a reduced-intensity regimen before allogeneic bone marrow transplantation works in treating patients with relapsed non-Hodgkin's or Hodgkin's lymphoma.
Timeline
- Start
- 2005-11-09
- Primary completion
- 2008-04
- Completion
- 2011-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pentostatin | Small molecule | 4 mg/m2 | Intravenous |
| Background | Cyclosporine | Peptide | — | Oral |
| Background | Methotrexate | Small molecule | 10 mg/m2 | Intravenous |
| Background | Mycophenolate Mofetil | Small molecule | 250 mg | Oral |